Show simple item record

dc.contributor.authorvan der Graaf, WTA
dc.contributor.authorOrbach, D
dc.contributor.authorJudson, IR
dc.contributor.authorFerrari, A
dc.date.accessioned2017-08-11T11:00:58Z
dc.date.issued2017-03-02
dc.identifier.citationThe Lancet. Oncology, 2017, 18 (3), pp. e166 - e175
dc.identifier.issn1470-2045
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/765
dc.identifier.eissn1474-5488
dc.identifier.doi10.1016/s1470-2045(17)30099-2
dc.description.abstractSurvival outcomes for adolescent and young adult patients with soft tissue sarcomas lag behind those of children diagnosed with histologically similar tumours. To help understand these differences in outcomes, we discuss the following issues with regard to the management of these patients with soft tissue sarcomas: delays in diagnosis, trial availability and participation, aspects of the organisation of care (with an emphasis on age-specific needs), national centralisation of sarcoma care, international consortia, and factors related to tumour biology. Improved understanding of the causes of the survival gap between adolescents and young adults with sarcomas will help drive new initiatives to improve final health outcomes in these populations. In this Review, we specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult soft tissue sarcomas diagnosed in adolescents and young adults, and discuss the age-specific needs of these patients.
dc.formatPrint-Electronic
dc.format.extente166 - e175
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectSarcoma
dc.subjectSoft Tissue Neoplasms
dc.subjectAdolescent
dc.subjectAdult
dc.subjectChild
dc.subjectYoung Adult
dc.titleSoft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts.
dc.typeJournal Article
dcterms.dateAccepted2016-11-10
rioxxterms.versionofrecord10.1016/s1470-2045(17)30099-2
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-03-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Lancet. Oncology
pubs.issue3
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.terms12 months
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamSarcoma Clinical Trialsen_US
dc.contributor.icrauthorJudson, Ian
dc.contributor.icrauthorvan der Graaf, Wilhelmina
dc.contributor.icrauthorMarsden,


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record